Cargando…
Massive immune response against IVIg interferes with response against other antigens in mice: A new mode of action?
Administration of high dose intravenous immunoglobulin (IVIg) is widely used in the clinic to treat autoimmune and severe inflammatory diseases. However, its mechanisms of action remain poorly understood. We assessed the impact of IVIg on immune cell populations using an in vivo ovalbumin (Ova)-immu...
Autores principales: | Sordé, Laetitia, Spindeldreher, Sebastian, Palmer, Ed, Karle, Anette |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5638328/ https://www.ncbi.nlm.nih.gov/pubmed/29023507 http://dx.doi.org/10.1371/journal.pone.0186046 |
Ejemplares similares
-
Tregitopes and impaired antigen presentation: Drivers of the immunomodulatory effects of IVIg?
por: Sordé, Laetitia, et al.
Publicado: (2017) -
Secukinumab, a novel anti–IL-17A antibody, shows low immunogenicity potential in human in vitro assays comparable to other marketed biotherapeutics with low clinical immunogenicity
por: Karle, Anette, et al.
Publicado: (2016) -
Aggregation of Human Recombinant Monoclonal Antibodies Influences the Capacity of Dendritic Cells to Stimulate Adaptive T-Cell Responses In Vitro
por: Rombach-Riegraf, Verena, et al.
Publicado: (2014) -
Secukinumab Demonstrates Significantly Lower Immunogenicity Potential Compared to Ixekizumab
por: Spindeldreher, Sebastian, et al.
Publicado: (2018) -
Author Correction: Secukinumab Demonstrates Significantly Lower Immunogenicity Potential Compared to Ixekizumab
por: Spindeldreher, Sebastian, et al.
Publicado: (2018)